Angiotensin receptor blockers use and lung cancer risk in Chinese patients with chronic obstructive pulmonary disease: a population-based cohort study.

IF 5.8 2区医学 Q1 Medicine

Respiratory Research Pub Date : 2025-05-15 DOI:10.1186/s12931-025-03248-z

Wenhao Li, Qingqing Yang, Yahong Chen, Yexiang Sun, Peng Shen, Feng Sun, Jinzhu Jia

{"title":"Angiotensin receptor blockers use and lung cancer risk in Chinese patients with chronic obstructive pulmonary disease: a population-based cohort study.","authors":"Wenhao Li, Qingqing Yang, Yahong Chen, Yexiang Sun, Peng Shen, Feng Sun, Jinzhu Jia","doi":"10.1186/s12931-025-03248-z","DOIUrl":null,"url":null,"abstract":"Background: Chronic obstructive pulmonary disease (COPD) is one of the most prevalent specific chronic respiratory diseases. It could worsen the development of cardiovascular diseases (CVD) and lung cancer. We aimed to elucidate the relationship between the use of angiotensin receptor blockers (ARBs) and the incidence of lung cancer among the COPD population in China.Methods: This retrospective cohort included COPD patients identified by the international classification of diseases 10th edition (ICD-10) codes in the Yinzhou Regional Health Care Database. The use of ARBs was defined according to the use and cumulative use. The lung cancer was defined by ICD-10 code (up to 2023). Time-varying Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of the use of ARBs on the risk of lung cancer.Results: This population-based COPD cohort comprised 25,436 patients with an average age of 68.2 years (standard deviation [SD]: 12.59 years), of which 60.6% were male. A total of 8,611 patients received at least one prescription for ARBs. After adjusting for multiple covariates, the results showed that cumulative annual exposure to ARBs was associated with a reduced risk of lung cancer (HR: 0.93, 95% CI: 0.90-0.97). The results of sensitivity analyses and negative control exposure analyses indicated that the associations were largely consistent and less likely to be influenced by unobserved confounding.Conclusions: The use of ARBs may reduce the risk of lung cancer among patients with COPD.","PeriodicalId":49131,"journal":{"name":"Respiratory Research","volume":"26 1","pages":"186"},"PeriodicalIF":5.8000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083003/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12931-025-03248-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is one of the most prevalent specific chronic respiratory diseases. It could worsen the development of cardiovascular diseases (CVD) and lung cancer. We aimed to elucidate the relationship between the use of angiotensin receptor blockers (ARBs) and the incidence of lung cancer among the COPD population in China.

Methods: This retrospective cohort included COPD patients identified by the international classification of diseases 10th edition (ICD-10) codes in the Yinzhou Regional Health Care Database. The use of ARBs was defined according to the use and cumulative use. The lung cancer was defined by ICD-10 code (up to 2023). Time-varying Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of the use of ARBs on the risk of lung cancer.

Results: This population-based COPD cohort comprised 25,436 patients with an average age of 68.2 years (standard deviation [SD]: 12.59 years), of which 60.6% were male. A total of 8,611 patients received at least one prescription for ARBs. After adjusting for multiple covariates, the results showed that cumulative annual exposure to ARBs was associated with a reduced risk of lung cancer (HR: 0.93, 95% CI: 0.90-0.97). The results of sensitivity analyses and negative control exposure analyses indicated that the associations were largely consistent and less likely to be influenced by unobserved confounding.

Conclusions: The use of ARBs may reduce the risk of lung cancer among patients with COPD.

Abstract Image

查看原文本刊更多论文

中国慢性阻塞性肺疾病患者血管紧张素受体阻滞剂的使用和肺癌风险：一项基于人群的队列研究

背景：慢性阻塞性肺疾病（COPD）是最常见的特异性慢性呼吸系统疾病之一。它可能会加剧心血管疾病（CVD）和肺癌的发展。我们的目的是阐明血管紧张素受体阻滞剂（ARBs）的使用与中国COPD人群肺癌发病率之间的关系。方法：本回顾性队列研究纳入鄞州地区卫生保健数据库中经国际疾病分类第10版（ICD-10）编码鉴定的COPD患者。根据使用和累积使用来定义arb的使用。肺癌的定义是ICD-10代码（截至2023年）。使用时变Cox比例风险模型来估计使用arb对肺癌风险的风险比（hr）和95%置信区间（CIs）。结果：以人群为基础的COPD队列包括25,436例患者，平均年龄为68.2岁（标准差[SD]: 12.59岁），其中60.6%为男性。共有8611名患者接受了至少一种arb处方。在对多个协变量进行调整后，结果显示arb的年累积暴露与肺癌风险降低相关（HR: 0.93, 95% CI: 0.90-0.97）。敏感性分析和阴性对照暴露分析的结果表明，这些关联在很大程度上是一致的，不太可能受到未观察到的混杂因素的影响。结论：使用arb可降低COPD患者发生肺癌的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory Research RESPIRATORY SYSTEM-

CiteScore

9.70

自引率

1.70%

发文量

314

审稿时长

4-8 weeks

期刊介绍： Respiratory Research publishes high-quality clinical and basic research, review and commentary articles on all aspects of respiratory medicine and related diseases. As the leading fully open access journal in the field, Respiratory Research provides an essential resource for pulmonologists, allergists, immunologists and other physicians, researchers, healthcare workers and medical students with worldwide dissemination of articles resulting in high visibility and generating international discussion. Topics of specific interest include asthma, chronic obstructive pulmonary disease, cystic fibrosis, genetics, infectious diseases, interstitial lung diseases, lung development, lung tumors, occupational and environmental factors, pulmonary circulation, pulmonary pharmacology and therapeutics, respiratory immunology, respiratory physiology, and sleep-related respiratory problems.